A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1950 participants.

Also called NCT07200921

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,950 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07200921
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07200921. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-10 (anticipated); primary completion 2028-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills
Acronym
TCM-ICH
Condition
Hypertensive Intracerebral Hemorrhage
Condition
Cerebral Small Vessel Diseases
Intervention (Drug)
Naoxuekang Dropping Pills
Intervention (Drug)
Naoxuekang Matching Placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
The Affiliated Hospital of Qingdao University (class: other)
Collaborator
Beijing Kangerfu Pharmaceutical Company Limited (class: not stated)

Record details

Record id
cardio:ct-nct07200921
Content hash
dd7083b0f5e091a57eca1496f180ae86a8f2668772daaa64267fd2a67964791c